The 340B Drug Pricing Program was intended to stretch federal resources by providing significant discounts to covered entities providing care to underserved populations. Program implementation and evidence of expanding services to higher income patients has brought more scrutiny and calls for elimination of the program. While additional review and reform may be warranted, profitability from 340B discounts enables covered entities to provide additional services that may not be feasible in absence of the program. This case report demonstrates one institution's use of 340B discounts to financially justify providing bedside medication delivery services for patients at the time of discharge from an inpatient admission. A simple financial model was developed using hospital data and inputs from available literature to estimate gross profit and earnings before interest, taxes, depreciation, and amortization (EBITDA) with and without 340B discounts. Without the 340B drug price discounts, the service would operate at a financial loss, and further investigation must be done to determine whether other clinical or economic benefits would warrant discharge medication delivery at the institution.
Introduction
Increasing pharmaceutical prices and hospital expansion of specialty services have led to a new focus on the utility of the 340B Drug Pricing Program. [1] [2] [3] [4] While the 340B program was established to stretch the resources for entities providing care to lower income individuals in response to rising drug prices in the early 1990's, current implementation has raised questions whether the program has actually benefitted the underserved populations for which it was designed. 3, 4 This paper describes a particular outpatient pharmacy service that would not be financially sustainable without the support of the pharmaceutical discounts provided by the 340B program and compares estimated earnings before interest, taxes, depreciation and amortization (EBITDA) with and without drug pricing discounts.
Medication delivery at discharge
Pharmacy led transitions of care (TOC) services are effective in reducing readmission rates and future hospital length of stay in addition to improving patient satisfaction and patient understanding of medications during discharge. 5, 6 Estimates show that approximately one third of patients do not fill their prescriptions which has shown to be a cause of readmissions, increased health costs and mortality in specific disease states. [7] [8] [9] The addition of a bedside delivery service for discharge prescriptions to improve TOC helps compliance and provides a new source of revenue for outpatient prescriptions. 5, 10 While top-line revenue is captured by increased outpatient prescription volume, publicly available estimates of the profitability of such programs are limited. Typically, reimbursements for non-specialty/discharge drugs are fairly similar for all pharmacies. However, costs of medications sold become a key factor when it comes to profit margin. For hospital systems, cost of medications for outpatient use can vary depending on purchasing power of the organization or if they qualify as a covered entity under the Health Resources and Services Administration's (HRSA) 340B program.
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A medication bedside delivery program was created within the authors' institution in 2014 initially targeting services with low patient turnover. Currently, medication bedside delivery service is administered and managed through outpatient pharmacy services. With limited hours and resources, not all patients being discharged from the hospital are able to utilize the services provided. Since the development and implementation of the bedside delivery service, the hospital has been looking to continually expand the program. Addition of more pharmacists, technicians, and pharmacy student educators have been looked into, as well as the expansion of service hours to provide 24/7 coverage for all patients being discharged. Prior to expansion, a financial analysis https://doi.org/10.1016/j.sapharm.2018.03.065 was conducted to evaluate the sustainability of the program with and without 340B discounts.
Methods
A financial analysis of medication bedside delivery in a large tertiary academic medical center was conducted utilizing outpatient pharmacy data from June 2015 to June 2016 to determine the financial benefits of current and expanded medication bedside delivery service. An economic model was developed by simulating theoretical scenarios based on historical hospital data and other published sources (Table 1) . Data included only information pertaining to directly measurable financial numbers such as direct revenue from filling discharge prescriptions. Multiple categories of costs for the system were considered and input into the simulation. Cost input was split into two categories: variable and fixed costs. Variable costs included cost-to-dispense per prescription, hourly wage for a bedside technician, current monthly technician labor hours, and average number of prescriptions dispensed per bedside technician. Technician labor costs were determined from the U.S. Bureau of Labor and Statistics. 12 Fixed costs included overhead equipment and training costs from the institution's procurement history. Cost-to-dispense, cost of goods sold for the drug dispensed, and other prescription estimates were gathered from historical bedside operational data as well as from estimates from the National Community Pharmacists Association and other published literature (Table 1) . [13] [14] [15] Economic benefits focused on direct financial benefits that included average prescription count and average prescription gross margin. Both average prescription count and average prescription gross margins were derived from existing bedside delivery units at the institution. Monetary benefits of interest were identified as revenue, gross profit, and EBITDA. For this study, revenue was defined as total reimbursements from insurance payers combined with patient out-of-pocket costs. Gross profit was determined by subtracting the cost of goods sold of the drug product, under each drug pricing scenario, from the total revenue. Pharmacy EBITDA was defined as gross profit minus the operational cost to dispense and wages needed to run the service. A Monte Carlo simulation was used to simulate profitability and estimate a 95% confidence interval for future operations using distributions from the prescriptions delivered within the sample time period. All analyses were completed with Microsoft Excel 2010 (Microsoft Corporation). This study was determined to be exempt from Institutional Review Board review on August 31, 2016 as it did not meet the definition of human subject research.
Results
The profitability of the current bedside delivery service (Table 2) demonstrated a net benefit when utilizing 340B pricing. The current base case prescription count was 939 monthly for bedside delivery services. Monthly gross profit and operating profit of current services were $33,025 and $11,030, respectively. However the financial costbenefit analysis utilizing non-340B prices demonstrated a negative financial benefit. For non-340B simulations of current bedside delivery assuming regular retail pricing, the monthly gross profit was $15,947 with the monthly operating loss of -$6047. Potential expansion of delivery services would operate at a loss if implemented in a regular retail acquisition cost scenario, but would be profitable in a 340B drug pricing scenario.
Discussion
By utilizing the 340B drug pricing program as a covered entity under HRSA, our current bedside delivery operations demonstrated a profit of $11,030 after the first month after accounting for direct variable and fixed costs. Expansion of these services throughout the hospital produces a positive EBITDA which could be reinvested in better patient care. However, without the 340B price discounts, this service would actually operate at a financial loss. This demonstrates the importance of participation in the 340B program for a large disproportionate share hospital.
Pharmacy evaluation of services to improve TOC has historically focused on metrics such as readmission, patient satisfaction, and medication error reduction. 10, 16, 17 These metrics may also impact reimbursement depending on the payer. However, readmission rates and patient satisfaction survey results are influenced by many factors, so it is difficult to measure the direct impact of a new pharmacy service on these scores. Our study was designed to measure financial operations directly attributable to the pharmacy department to determine whether a medication bedside delivery service would produce a positive net financial benefit to the hospital, without the potential bias of including other variables that may be multifactorial. This approach to improve the internal validity of the measures did not consider downstream clinical or economic effects of patients receiving their medications at discharge, which may severely underestimate the total benefit. Hospital administrators considering implementation of outpatient pharmacy delivery services should evaluate all direct financial costs as well as the potential benefits of increased medication adherence, the impact on patient readmission, medication errors at discharge, or patient satisfaction with hospital services. This simulation demonstrates that 340B covered entities would financially benefit from medication bedside delivery by investing in technology and pharmacy technicians trained to operate the service. Covered entities with an existing outpatient pharmacy or with an established contract pharmacy with the ability to bill outpatient prescription insurance companies would benefit the most. We did not investigate the cost of starting a brand new outpatient pharmacy in order to begin bedside delivery. Hospitals without existing outpatient pharmacy relationships would need to consider startup pharmacy costs as well as costs of contracting the service to an external community pharmacy.
Study limitations
There were multiple limitations with the present study. First, bedside delivery technicians and workflow at the present institution were not at maximum operational efficiency during the data collection period. This potentially overestimates the variable technician cost. Additional challenges identified in creation of a new delivery service included developing a relationship and workflow with pharmacy technicians and discharge coordinators, troubleshooting prior authorizations, having providers change scripts based on patient's insurance, privacy concerns with point of sale devices, and timing of shifts to capture the majority of discharges. These challenges were not measured directly in our model but may account for higher cost estimates in our model inputs. Since the start of the service and running of the simulation, bedside delivery technicians have been increasing the number of units they service. The current bedside delivery program has already expanded to nine additional units without the need of any additional pharmacy staff. Therefore, when expanding services, the profit margins stated from the simulation may be underestimated as we continually see efficiency and workflow process improvement. Depreciation of assets acquired as fixed costs in our model (computers, point of sale devices, and tablets) were not included as we assumed the replacement costs would not be incurred in our short time horizon. Longer program evaluation should consider future technology upgrades or other investments. Additionally, our fixed costs included a laptop computer on a mobile workstation which may be more expensive compared to other technology options.
Implications
Expansion of bedside delivery services in 340B-eligible health systems provide a direct financial benefit to the institution in addition to ensuring patients leave at discharge with a medication in-hand. For non-340B entities, the financial benefit may hinge on the leverage of drug pricing discounts through purchasing agreements and would need to be further evaluated. Our model may serve as a template or guide for others to substitute our inputs with their own to make the final determination.
Conclusion
Existing outpatient pharmacy bedside delivery services are financially beneficial to an institution participating in the 340B drug pricing program. Without the 340B drug price discounts, the service would operate at a financial loss, and further investigation must be done to determine whether other clinical or economic benefits would warrant medication delivery at the institution.
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